... myeloablative agonists MeSH D27.505.954.329 - antirheumatic agents MeSH D27.505.954.329.030 - anti-inflammatory agents, non- ... myeloablative agonists MeSH D27.505.696.510 - muscle relaxants, central MeSH D27.505.696.543 - narcotic antagonists MeSH ... adrenergic agonists MeSH D27.505.519.625.050.100.100 - adrenergic alpha-agonists MeSH D27.505.519.625.050.100.200 - adrenergic ... adrenergic agonists MeSH D27.505.696.577.050.100.100 - adrenergic alpha-agonists MeSH D27.505.696.577.050.100.200 - adrenergic ...
... agonists, CD40 agonists, anti-PD-1 (pembrolizumab, pidilizumab, and nivolumab) and PD-L1 antibodies. Evidence suggests that ... November 2008). "Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative ...